Thiogenesis Therapeutics (TSXV:TTI) Cash-to-Debt : No Debt ⁽¹⁾ (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Thiogenesis Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Thiogenesis Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Thiogenesis Therapeutics's Cash-to-Debt or its related term are showing as below:

TSXV:TTI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: No Debt Max: No Debt
Current: No Debt

During the past 5 years, Thiogenesis Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.06. And the median was No Debt.

TSXV:TTI's Cash-to-Debt is ranked better than
99.87% of 1521 companies
in the Biotechnology industry
Industry Median: 6.39 vs TSXV:TTI: No Debt

Thiogenesis Therapeutics Cash-to-Debt Historical Data

The historical data trend for Thiogenesis Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Thiogenesis Therapeutics Cash-to-Debt Chart

Thiogenesis Therapeutics Annual Data

Trend

Dec19

Dec20

Feb21

Feb22

Dec23

Cash-to-Debt

No Debt

0.06

N/A

No Debt

Thiogenesis Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Sep21	Feb22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial								No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Thiogenesis Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Thiogenesis Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thiogenesis Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's Cash-to-Debt falls into.

Thiogenesis Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Thiogenesis Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Thiogenesis Therapeutics had no debt ⁽¹⁾.

Thiogenesis Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Thiogenesis Therapeutics had no debt ⁽¹⁾.

Thiogenesis Therapeutics (TSXV:TTI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Thiogenesis Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Thiogenesis Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Thiogenesis Therapeutics (TSXV:TTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6

Website

https://www.thiogenesis.com

Thiogenesis Therapeutics Corp is a clinical stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's lead compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live and side effects. TTI-0102's initial applications are for mitochondrial disease, Rett syndrome and pediatric NASH.

Executives

Vincent P. Stanton

10% Security Holder